Shannon Ferry, PhD

Currently: Postdoctoral Fellow, University of Rochester
MCB alumna (Huang Lab)

 

About Me

I first became fascinated in immunology while pursuing my undergraduate degree at the University of Rochester. My experiences as an undergraduate led me to stay in Rochester to work as a lab technician. My work focused on designing novel cytokine-based cancer immunotherapies. I joined the Huang lab in the Spring of 2021. My thesis project focuses on engineering armored CAR T and NK cells for clinical use and better understanding how this therapy combats immunosuppression in the solid tumor microenvironment. Outside of lab, I enjoy running, hiking, and baking.

 

Publications

Ferry SL, Abdullah L, Balasubramanian A, Nowak E, Carl A, Turnquist A, Mohamed AO, Usherwood EJ, Sundrud M, Huang YH. Systemic pre-conditioning favors effector over exhausted CD8 T cell subsets following Sup2-IL33 armored CAR T cell therapy. J Immunother Cancer 2026 Jun 3;14(6):e013020. doi: 10.1136/jitc-2025-013020.

Mohamed AO, Boone, DT, Ferry SL, Peck MC, Santos AM, Soderholm HE, Wittling MC, Paulos C, Turk MJ, Huang YH. CD4 T cell depletion increases memory differentiation of endogenous and CAR T cells and enhances the efficacy of Super2 and IL-33-armored CAR T cells against solid tumors. J Immunother Cancer 2025 Feb 11;13(2):e009994. doi: 10.1136/jitc-2024-009994. PMID: 39933839.

Brog RA, Ferry SL, Schiebout CT, Messier CM, Cook WJ, Abdullah L, Zou J, Kumar P, Sentman CL, Frost HR, Huang YH. Superkine IL2 and IL33 armored CAR T cells reshape the tumor microenvironment and reduce growth of multiple solid tumors. Cancer Immunol Res Epub 20220613. doi: 10.1158/2326-6066.CIR-21-0536. PubMed PMID: 35696724.